On Tuesday, Axsome Therapeutics received a positive adjustment to its Relative Strength (RS) Rating, from 87 to 93.
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the best-performing stocks tend to have an RS Rating north of 80 as they launch their biggest climbs.
How To Use Stock Charts To Stay Profitable And Protected
Axsome Therapeutics has moved more than 5% past a 105.00 entry in a second-stage consolidation, meaning it's now out of a proper buy range. Look for the stock to create a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Axsome Therapeutics posted 0% EPS growth last quarter. Sales gains came in at 81%. The company is expected to report its latest performance numbers on or around Feb. 18.
The company holds the No. 23 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
